

# INPLASY PROTOCOL

To cite: Wang et al. Effect of yangyin jiangtang tablet on type 2 diabetes mellitus A protocol for systematic review and meta-analysis. Inplasy protocol 202140139. doi: 10.37766/inplasy2021.4.0139

## Effect of yangyin jiangtang tablet on type 2 diabetes mellitus A protocol for systematic review and meta-analysis

Wang, X<sup>1</sup>; Zhang, LQ<sup>2</sup>; Ma, MJ<sup>3</sup>.

Received: 27 April 2021

Published: 28 April 2021

**Corresponding author:**  
Xiangli Wang

13783526226@163.com

**Author Affiliation:**  
Dongming Road Campus,  
Henan University of Traditional  
Chinese Medicine

**Support:** Special Project of  
Traditiona.

**Review Stage at time of this  
submission:** The review has  
not yet started.

**Conflicts of interest:**  
None declared.

**Review question / Objective:** P: type 2 diabetic patient; I: On the basis of conventional treatment combine yangyin jiangtang tablet; C: conventional therapy; O: fasting glucose, postprandial 2h glucose, insulin levels and treatment response rates.

**Condition being studied:** Type 2 diabetes mellitus. At present, each retrieval database has been retrieved, and the next step is screening and analysis.

**Information sources:** We will search the databases of Pubmed, Cochrane Library, Web of Science, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge infrastructure (CNKI), Chinese Scientific Journal Database(VIP), and Wanfang database from the date of establishment to April 27, 2021.

**INPLASY registration number:** This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 28 April 2021 and was last updated on 28 April 2021 (registration number INPLASY202140139).

### INTRODUCTION

**Review question / Objective:** P: type 2 diabetic patient; I: On the basis of conventional treatment combine yangyin jiangtang tablet; C: conventional therapy; O: fasting glucose, postprandial 2h

glucose, insulin levels and treatment response rates.

**Condition being studied:** Type 2 diabetes mellitus. At present, each retrieval database has been retrieved, and the next step is screening and analysis.

---

## METHODS

**Participant or population:** Type 2 diabetic patient.

**Intervention:** On the basis of conventional treatment combine yangyin jiangtang tablet.

**Comparator:** Conventional therapy.

**Study designs to be included:** This study will include a randomized controlled trial (RCT) to examine the effect of Yangyin Jiangtang Tablet on type 2 diabetes. Non-randomized controlled trials, animal trials, reviews and conference summaries will not be included in the criteria.

**Eligibility criteria:** All patients who are diagnosed with type 2 diabetes, and there is no restriction on age, gender, economic status and educational level of patients.

**Information sources:** We will search the databases of Pubmed, Cochrane Library, Web of Science, EMBASE, Chinese Biomedical Literature Database (CBM), China National Knowledge infrastructure (CNKI), Chinese Scientific Journal Database(VIP), and Wanfang database from the date of establishment to April 27, 2021.

**Main outcome(s):** The main outcomes were fasting glucose, postprandial 2h glucose, insulin levels and treatment response rates.

**Quality assessment / Risk of bias analysis:** The two investigators will use the Cochrane collaborations tool installed in RevMan V.5.3 to independently assess the risk of bias the included studies, including seven items: random sequence generation, assignment concealment, subject-intervener blinding, outcome reviewer blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. The assessment is divided into three risk levels: low risk, unclear risk and high risk. If the included studies fully meet the above criteria, the risk of bias is low, and the literature quality grade is "A"; If the included part of the study meets the above criteria, it indicates a medium risk of

bias and the literature quality grade is "B". If the included studies do not meet the above criteria at all, it indicates a high risk of bias and the literature quality grade is "C". If there is a disagreement between two researchers, discuss and communicate with the third party.

**Strategy of data synthesis:** We will search the following databases to collect relevant studies: Pubmed, Cochrane Library, Web of Science, EMBASE, Chinese Biomedical Literature Database(CBM), CNKI, VIP, and Wanfang database until April 27, 2021. In addition, in order to obtain grey literature, references included in the literature will be manually retrieved. The search terms include Yangyin Jiangtang Tablet, type 2 diabetes. The specific search strategy performed in Pubmed will be presented in Table 1.

**Subgroup analysis:** None.

**Sensitivity analysis:** In order to maintain the stability of the survey results, the sensitivity of the results will be analyzed. We will exclude each study included in the results analysis one by one, and then re-analyze the data and compare the differences with the original results to assess the factors that influenced the results, so that we can determine whether the results are reliable.

**Country(ies) involved:** China.

**Keywords:** yangyin jiangtang tablet, Type 2 Diabetes Mellitus, meta-analysis, protocol, systematic review.

**Contributions of each author:**

Author 1 - Xiangli Wang.

Author 2 - Liuqiao Zhang.

Author 3 - Mengjie Ma.